Literature DB >> 31691207

Li-Fraumeni syndrome heterogeneity.

P Gargallo1, Y Yáñez2, V Segura2, A Juan3, B Torres3, J Balaguer3, S Oltra4,5, V Castel3, A Cañete3.   

Abstract

Clinical variability is commonly seen in Li-Fraumeni syndrome. Phenotypic heterogeneity is present among different families affected by the same pathogenic variant in TP53 gene and among members of the same family. However, causes of this huge clinical spectrum have not been studied in depth. TP53 type mutation, polymorphic variants in TP53 gene or in TP53-related genes, copy number variations in particular regions, and/or epigenetic deregulation of TP53 expression might be responsible for clinical heterogeneity. In this review, recent advances in the understanding of genetic and epigenetic aspects influencing Li-Fraumeni phenotype are discussed.

Entities:  

Keywords:  Epigenome; Genotype; Li–Fraumeni syndrome; Pediatrics; Phenotype

Year:  2019        PMID: 31691207     DOI: 10.1007/s12094-019-02236-2

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  8 in total

Review 1.  Normal and Neoplastic Growth Suppression by the Extended Myc Network.

Authors:  Edward V Prochownik; Huabo Wang
Journal:  Cells       Date:  2022-02-21       Impact factor: 6.600

2.  The features of acute lymphocytic leukemia with intracranial germinoma in a patient with Li-Fraumeni syndrome: a case description.

Authors:  Yiwen Liang; Ke Wei; Weiguo Cao
Journal:  Quant Imaging Med Surg       Date:  2022-03

3.  Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.

Authors:  Kelvin César de Andrade; Payal P Khincha; Jessica N Hatton; Megan N Frone; Talia Wegman-Ostrosky; Phuong L Mai; Ana F Best; Sharon A Savage
Journal:  Lancet Oncol       Date:  2021-11-12       Impact factor: 41.316

Review 4.  Correlation of molecular alterations with pathological features in hepatocellular carcinoma: Literature review and experience of an Italian center.

Authors:  Thais Maloberti; Antonio De Leo; Viviana Sanza; Elisa Gruppioni; Annalisa Altimari; Mattia Riefolo; Michela Visani; Deborah Malvi; Antonia D'Errico; Giovanni Tallini; Francesco Vasuri; Dario de Biase
Journal:  World J Gastroenterol       Date:  2022-07-07       Impact factor: 5.374

5.  Germline TP53 c.566C>T mutation incidentally diagnosed during treatment for acute myeloid leukemia: A case report.

Authors:  Hiroshi Sato; Seiki Matsuo; Yukiko Ando; Yuko Imamura; Masaya Hirose
Journal:  Clin Case Rep       Date:  2021-12-16

Review 6.  Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome.

Authors:  Pan Pantziarka; Sarah Blagden
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

Review 7.  Hyperactivating p53 in Human Papillomavirus-Driven Cancers: A Potential Therapeutic Intervention.

Authors:  Nigel A J McMillan; Adi Idris; Yusuf M Idres
Journal:  Mol Diagn Ther       Date:  2022-04-05       Impact factor: 4.074

8.  Association between Predicted Effects of TP53 Missense Variants on Protein Conformation and Their Phenotypic Presentation as Li-Fraumeni Syndrome or Hereditary Breast Cancer.

Authors:  Yaxuan Liu; Olga Axell; Tom van Leeuwen; Robert Konrat; Pedram Kharaziha; Catharina Larsson; Anthony P H Wright; Svetlana Bajalica-Lagercrantz
Journal:  Int J Mol Sci       Date:  2021-06-14       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.